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The human choroid is capable of rapidly changing its thickness in response to a variety of stimuli.
However little is known about the role of the autonomic nervous system in the regulation of the
thickness of the choroid. Therefore, we investigated the effect of topical parasympatholytic and sym-
pathomimetic agents upon the choroidal thickness and ocular biometrics of young healthy adult sub-
jects. Fourteen subjects (mean age 27.9 ± 4 years) participated in this randomized, single-masked,
placebo-controlled study. Each subject had measurements of choroidal thickness (ChT) and ocular bio-
metrics of their right eye taken before, and then 30 and 60 min following the administration of topical
pharmacological agents. Three different drugs: 2% homatropine hydrobromide, 2.5% phenylephrine hy-
drochloride and a placebo (0.3% hydroxypropyl methylcellulose) were tested in all subjects; each on
different days (at the same time of the day) in randomized order. Participants were masked to the
pharmacological agent being used at each testing session. The instillation of 2% homatropine resulted in a
small but signiﬁcant increase in subfoveal ChT at 30 and 60 min after drug instillation (mean change
7 ± 3 mm and 14 ± 2 mm respectively; both p < 0.0001). The parafoveal choroid also exhibited a similar
magnitude, signiﬁcant increase in thickness with time after 2% homatropine (p < 0.001), with a mean
change of 7 ± 0.3 mm and 13 ± 1 mm (in the region located 0.5 mm from the fovea center), 6 ± 1 mm and
12.5 ± 1 mm (1 mm from the fovea center) and 6 ± 2 mm and 12 ± 2 mm (1.5 mm from the fovea center)
after 30 and 60 min respectively. Axial length decreased signiﬁcantly 60 min after homatropine
(p < 0.01). There were also signiﬁcant changes in lens thickness (LT) and anterior chamber depth (ACD)
(p < 0.05) associated with homatropine instillation. No signiﬁcant changes in choroidal thickness, or
ocular biometrics were found after 2.5% phenylephrine or placebo at any examination points (p > 0.05).
In human subjects, signiﬁcant increases in subfoveal and parafoveal choroidal thickness occurred after
administration of 2% homatropine and this implies an involvement of the parasympathetic system in the
control of choroidal thickness in humans.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The choroid is a highly vascularised layer that plays an impor-
tant role in normal ocular function. It supplies the outer retinawith
oxygen and nutrients under highly regulated blood ﬂow, acts as a
heat diffuser that protects the photoreceptors and also secretes
growth factors (Nickla and Wallman, 2010). The choroid also
directly modulates the intraocular pressure (IOP) via vasomotor
control of blood ﬂow and indirectly through its role in uveoscleral
outﬂow. Given the vascular nature of the tissue, the choroid's
morphology is mainly determined by the course and branching).
Ltd. This is an open access article upattern of the ciliary arteries (Bill et al., 1983). It also contains non-
vascular smooth muscle cells, a network of spindle- or star-shaped
cells that are thought to play a role in altering the thickness of the
choroid under the inﬂuence of local mediators and intrinsic
choroidal neurons that receive input from the sympathetic and
parasympathetic nervous system (Nickla and Wallman, 2010;
Lütjen-Drecoll, 2006).
Advances in spectral domain optical coherence tomography
(SD-OCT) technology have enabled the visualisation and reliable
measurements of the human choroid (Ikuno et al., 2010; Hirata
et al., 2011; Ouyang et al., 2011). Estimates of the average sub-
foveal choroidal thickness in the healthy eyes of adult populations
(age 18 and over) have ranged between 192 and 354 mmdependent
upon the age and refractive error distribution of the populationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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topographical variations in the choroidal thickness across the
posterior pole have also been found, with the choroid consistently
reported to be thicker superiorly and temporally, compared to nasal
and inferior regions (Hirata et al., 2011; Ouyang et al., 2011). Recent
clinical studies have found changes in ChT to be associated with a
number of ocular diseases, such as central serous chorioretinopathy
(Maruko et al., 2011b), polypoidal choroidal vasculopathy (Koizumi
et al., 2011), age related macular degeneration (Manjunath et al.,
2011), inﬂammatory eye diseases (Maruko et al., 2011a), inherited
retinal dystrophies (Yeoh et al., 2010), diabetic retinopathy
(Esmaeelpour et al., 2011), and glaucoma (Maul et al., 2011).
Changes in the thickness of the human choroid have also been
found associated with age (Manjunath et al., 2011) and the pres-
ence of refractive error (Ikuno et al., 2010; Hirata et al., 2011). Short
term changes in human choroidal thickness have also been re-
ported, associated with time of the day (Brown et al., 2009;
Chakraborty et al., 2011; Tan et al., 2012), smoking (Sızmaz et al.,
2013), caffeine intake (Vural et al., 2014) and with imposed
retinal image blur (i.e. hyperopic and myopic defocus) (Read et al.,
2010; Chakraborty et al., 2012, 2013).
Additionally, evidence from animal studies suggests that short-
term changes in the thickness of the choroid associated with retinal
image blur are related to longer term changes in eye growth and the
development of refractive errors (Wallman et al., 1995). The
magnitude of choroidal thickness variations in relation to defocus
found in humans (Read et al., 2010; Chakraborty et al., 2012, 2013)
and mammals (Hung et al., 2000) are substantially smaller than
those found in avian species (Wallman et al., 1995). Furthermore,
several non-selective and selective (M4) muscarinic antagonists
have been found to cause a transient thickening of the choroid in
chicks (Nickla et al., 2013) or to prevent the choroidal thinning that
is normally associated with form-deprivation myopia (McBrien
et al., 2011). In contrast, a number of non-speciﬁc muscarinic ago-
nists stimulated eye elongation and choroidal thinning in intact
chicken eyes (Nickla et al., 2013).
Although the exact mechanism underlying reports of short-
term changes in choroidal thickness is not known, previous
studies have revealed a rich autonomic vasoactive nerve supply to
the choroid involving the activation of sympathetic adrenergic and
parasympathetic muscarinic receptors (Neuhuber and Schr€odl,
2011). Parasympathetic nerves derived from the pterygopalatine
ganglion, via the facial nerve, form a dense perivascular plexus
around the choroidal vessels and mediate an increase in blood ﬂow
by vasodilatation. These ﬁbres also terminate on non-vascular
smooth muscle cells and modulate their tonus (Nickla and
Wallman, 2010; Neuhuber and Schr€odl, 2011). In addition, the
choroid receives innervation from the ciliary ganglion, via the oc-
ulomotor nerve that terminates on blood vessels and non-vascular
smooth muscle. However, the role of these ﬁbres in the regulation
of choroidal blood ﬂow in mammals is not well established,
compared to birds where they comprise the main parasympathetic
input to the choroid (Nickla and Wallman, 2010; Neuhuber and
Schr€odl, 2011). A dense sympathetic innervation originates from
the ipsilateral superior cervical ganglion, its stimulation causes
choroidal vasoconstriction mainly via activation of a1eadrenergic
receptors located in the smoothmuscle cells of the vessels (Lanigan
et al., 1988). Apart from the autonomic innervation, the choroid also
receives the sensory ﬁbres that arise from the trigeminal ganglion
via ophthalmic nerve that exert a vasodilatatory inﬂuence on
choroidal blood ﬂow through local effector function-“axon reﬂex”
in addition to the sensory functions (Nickla and Wallman, 2010;
Neuhuber and Schr€odl, 2011).
The rich autonomic innervation to various choroidal structures
suggests a potential involvement of the autonomic system in theregulation of choroidal thickness, either through modulation of
choroidal blood ﬂow, and/or alterations in the tone of non-vascular
smooth muscle (Nickla and Wallman, 2010).
We have examined the effects of the modiﬁcation of the auto-
nomic nervous system activity upon choroidal thickness through
the use of topical parasympatholytic and sympathomimetic agents.
This was measured with SD-OCT at 30 and 60 min after cholinergic
blockade or adrenergic stimulation on different days in healthy
young adults. By investigating ocular biometry after topical
adrenergic and anticholinergic agent administration, we hoped to
improve our understanding of the mechanisms regulating the
thickness of the choroid in humans.
2. Material and methods
2.1. Subjects
Fourteen young healthy subjects (mean age 27.9 ± 4 years)
participated in this randomized, single-masked, placebo-controlled
study. The study and protocol conformed to the tenets of the
Declaration of Helsinki and was approved by the university human
research ethics committee. Subjects were recruited primarily from
the students and staff of the university. Sixty four percent of the
participants (n ¼ 9) were male and 50% were Caucasian (Caucasian
n ¼ 7, Indian ¼ 6, East Asian n ¼ 1). Written informed consent was
obtained from participants after thorough explanation of the na-
ture and risks of the experiment before commencement of the
study. None of the participants had any signiﬁcant ocular or sys-
temic disease and had no history of ocular injury or surgery.
Before the study, each participant underwent a full eye exami-
nation to determine their refractive status and to ensure they met
the criteria of good ocular health. All subjects had normal visual
acuity of logMAR 0.00 or better. Their mean spherical equivalent
refractive error was0.62 ± 1.42 DS (range4.00 toþ0.75 DS). The
majority of participants exhibited low refractive errors (þ0.75
to 0.75 DS) with only 2 subjects with myopic refractive
errors > 0.75 DS. No participant exhibited anisometropia of
greater than 1.00 DS or cylindrical refraction of greater than
1.00 DC. Two of the participants were soft contact lens wearers, but
they ceased lens wear one week prior to participation in the
experiment and did not wear lenses for the duration of their
involvement in the experiment. To limit the potential confounding
inﬂuence of ocular diurnal variations upon the results (Chakraborty
et al., 2011), all three experimental conditions were tested at
approximately the same time of day between 9 am and 2 pm on
different days, in randomized order, for each subject.
2.1.1. Pharmacologic agents
Only the right eyes were treated with either: one drop of 2%
homatropine hydrobromide, or one drop of 2.5% phenylephrine
hydrochloride or placebo (consisting of 0.3% hydroxypropyl
methylcellulose) over three separate days, with a different phar-
macological agent tested at each visit in randomized order.
Homatropine hydrobromide is a non-selective anticholinergic
agent that is closely related to atropine (although it has shorter
lasting mydriatic and cycloplegic effects), while phenylephrine is a
selective a1-adrenergic agonist. The drug doses were chosen based
on the dosage that is commonly used in clinical practice, since these
doses are known to be safe and to have a clinically signiﬁcant
pharmacological effect on the iris and ciliary body function. The
doses are also predicted to exceed the published ED50 values of
phenylephrine (Theoﬁlopoulos et al., 1988) and homatropine
(Smith, 1976). To prevent contamination of a trial due to the re-
sidual action of a previously administered agent, a washout period
up to ten times the terminal elimination half-life of the drug was
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study have terminal half-lives ranging from 2.5 to 3 h and 3.8e4.8 h
for phenylephrine and homatropine respectively (Dart, 2004;
Gambill et al., 1967). Therefore a washout period of at least 48 h
after the use of each agent was implemented. Participants were
masked to the pharmacological agent being used at each testing
session. All eye drops were instilled into the inferior conjunctival
sac, and participants were directed to close their eyes for approx-
imately 1 min following drop instillation to limit loss of medication
through the nasolacrimal drainage system and to maximise ocular
drug contact.
2.2. Procedures
On each of the three testing days, all subjects had a series of
ocular measurements taken before and 30 and 60 min following
the instillation of one drop of the pharmaceutical agent. The room
lighting was kept at low photopic levels for all subjects throughout
the entire protocol (room illuminance was ~10 lux).
The retinal and choroidal thickness measurements were ob-
tained with the SOCT Copernicus HR (Optopol Technology S.A.
Zawiecie, Poland). The SOCT Copernicus HR is a spectral domain
optical coherence tomographer that provides high-resolution,
cross-sectional images of the posterior eye. The instrument uses a
super-luminescent diode light source with centre wavelength of
850 nm (bandwidth 100 nm) and has an axial resolution of 3 mm
and transverse resolution of 12e18 mm. The Copernicus HR scans
the retina and choroid at 52,000 A-scans per second. Recent studies
have shown that this instrument provides reliable measurements
of both retinal and choroidal thickness (Wolf-Schnurrbush et al.,
2009; Benavente-Perez et al., 2010).
Three series of OCT scans (6 mm length “cross” scans that cap-
ture a set of horizontal and vertical line scans each centred on the
fovea; with each series of scans consisting of 30 B-Scans, each with
999 A-scans) were collected from the right eye of each participant
at each measurement session and were later averaged. To enhance
the signal from the choroid, the “chorioretinal” scanning mode of
the instrument was used. Only scans with an image quality index
(QI) of more than 4 (mean ± SD was 6.3 ± 1.1) were included in
analysis to allow reliable detection of the RPE and chorioscleral
interface in the analysed OCT images.
Ocular biometrics before and after instillation of each of the
three agents were also assessed with a non-contact biometer
(Lenstar LS 900; Haag Streit AG, Koeniz, Switzerland). ThisFig. 1. Schematic diagram of the experimental set-up for ocular biometry measure-
ments using a periscope system (consisting of a pair of mirrors (M1 and M2), and a
correcting lens) with the Lenstar and a correcting lens that allows ocular biometry to
be measured along the line of sight with relaxed accommodation under binocular
dichoptic ﬁxation.instrument is based on the principle of low coherence optical
reﬂectometry and it provides accurate and reliable measures of
axial length (AL), central corneal thickness (CCT), corneal curvature,
lens thickness (LT) and anterior chamber depth (ACD) along the
visual axis in a single measurement procedure (Buckhurst et al.,
2009; Cruysberg et al., 2010; Holzer et al., 2009). The instrument
calculates the axial length based upon the distance between the
anterior cornea and the retinal pigment epithelium. The anterior
corneal curvature measures are based upon analysis of the image of
32 reference points reﬂected from the anterior corneal surface
oriented in 2 circles at approximately the 2.3 and 1.65 mm optical
zones. Since the Lenstar does not allow control of accommodation
when viewing the instrument's internal ﬁxation target, the bio-
metric measurements may potentially be inﬂuenced by accom-
modation. Therefore, accommodation control was achieved with a
periscope system consisting of a pair of 45 mirrors and trial frame
(in order to provide the full distance spherical equivalent refractive
correction to the fellow eye) mounted in front of the Lenstar (Fig.1).
The periscope system allowed two different stimuli to be presented
to the two eyes (the biometer's internal ﬁxation target to the right
eye and an external target at 6m to the left eye) leading to dichoptic
(simultaneous) presentation of the stimuli and therefore allowing
the biometric measurements to be captured during relaxed ac-
commodation. Before the measurements were carried out, care was
taken to ensure the centre of the external target (a high-contrast,
Maltese cross) was aligned precisely with the centre of the in-
strument's measurement beam to ensure on axis (foveal)
measurements.
Thus, the fellow eye viewed a free-space target consisting of a
Maltese cross placed at the eye's far point (~0 D accommodative
demand) through the trial lens, while the treated (right) eye saw
the biometer's ﬁxation target. Subjects were instructed to keep the
Maltese cross target in sharp focus throughout all measurements
and to report any misalignment between the two targets. Five
consecutive measurements were collected from each subject at
each measurement session and were later averaged.
IOP was also measured at each session using the Ocular
Response Analyser instrument (ORA; Reichert, Depew, NY). The
ORA provides reliable IOP measurements: IOPg, which is calibrated
against Goldman applanation tonometry and IOPcc which takes
corneal biomechanical properties into account and has been re-
ported to be less affected by corneal properties than other tono-
metric techniques (Luce, 2005). The mean IOPcc was calculated for
each subject at each measurement session from a total of four
readings.
2.3. Data analysis
The retinal and choroidal thickness data obtained from the SOCT
Copernicus HR were extracted from the OCT images and calculated
with a two-step method. In the ﬁrst step, all 30 individual scans
along the horizontal and vertical scan lines in each series of scans
were aligned to provide average horizontal and vertical B-scan
images with reduced speckle noise and increased visibility of the
retinal layers and the chorioscleral interface (Alonso-Caneiro et al.,
2011). In the second step, an experienced masked observer
manually segmented the average B-scan images (3 horizontal and 3
vertical images at each measurement session) to derive retinal and
choroidal thickness. The observer selected 16 points along three
boundaries in each OCT image: the inner boundary of the inner
limiting membrane (ILM), the outer boundary of the RPE and the
inner border of the chorioscleral interface across the 6 mm length
of each average image and the software automatically ﬁtted a
smooth function (spline ﬁt) to these points. The observer also
manually selected the center of the fovea on each average OCT scan.
Table 1
Summary of within-session repeatability for each of the ocular variables measured
at each measurement session.
Mean within-session
standard deviation
Mean coefﬁcient of
variation (%)
ICC
AxL (mm) 0.007 0.03 0.998
CCT (mm) 0.002 0.35 0.998
ACD (mm) 0.011 0.41 0.998
LT (mm) 0.014 0.45 0.996
Subfoveal ChT (mm) 0.002 0.78 0.998
Parafoveal (0.5 mm)
ChT (mm)
0.002 0.84 0.998
Parafoveal (1.0 mm)
ChT (mm)
0.003 0.98 0.997
Parafoveal ChT (mm) 0.004 1.65 0.992
RT (mm) 0.003 1.45 0.996
Keratometry (D) 0.165 0.38 0.987
IOPcc (mm Hg) 1.158 8.32 0.903
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(Odell et al., 2011), the transverse scale of the images was adjusted
based upon the participant's AL obtained with the Lenstar (Lenstar
LS 900; Haag Streit AG) using an approach similar to that described
by Wagner-Schuman et al. (2011).
Based on the manual segmentation, the average foveal retinal
thickness (distance between the ILM and the RPE at foveal centre)
as well as the average subfoveal and parafoveal ChT (distance be-
tween the outer boundary of the RPE and the inner boundary of the
chorioscleral interface, in nasal, superior, temporal and inferior
quadrants, extending to 1.5 mm from the fovea average at 0.5 mm
intervals) were calculated at each measurement session. The indi-
vidual sectors were referred to as the “average subfoveal choroidal
thickness” (for the thickness at the center of the fovea), nasal, su-
perior, temporal and inferior parafoveal thickness (for the average
ChT from 0.5 mm away from foveal center to 1.5 mm from the
foveal center). Fig. 2 illustrates an example of an average OCT image
from a representative subject, along with an overview of the retinal
and choroidal segmentation and analysis procedure used in the
study.
Following data collection, the average of all the biometric pa-
rameters (AL, CCT, corneal curvature, ACD, LT, RT, subfoveal ChT and
parafoveal ChT) and IOP for each participant at each measurement
session were calculated. The KolmogoroveSmirnov test revealed
that data from all variables did not depart signiﬁcantly from a
normally distributed sample (p > 0.05). A repeated-measures
analysis of variance (ANOVA) with two within-subject factors
(time and drug) was carried out for each of the measured variables
to determine the signiﬁcance of changes in each of the ocular pa-
rameters after instillation of the pharmaceutical agents. Bonferroni
corrected pairwise comparisons were used to examine individual
differences for any variables with signiﬁcant withinesubject effects
and interactions. Additionally, for the parafoveal choroidal thick-
ness data, two additional within-subject factors (parafoveal region
[0.5 mm, 1 mm, 1.5 mm from the fovea center] and quadrant
[temporal, nasal, superior and inferior]) were included in the
ANOVA.
To provide an assessment of thewithin-session precision of each
of the ocular parameters measured, the within-session SD and
coefﬁcient of variation (i.e., the within-session SD divided by the
mean, expressed as a percentage) of the repeatedmeasures for each
variable collected at each session were calculated as described byFig. 2. Example of a representative average OCT image from one subject (derived from the a
captured (i.e. 3 vertical and 3 horizontal average images at each measurement session) fo
border of the RPE and inner border of the chorioscleral interface (white lines) in each image
the outer border of the RPE. The subfoveal and parafoveal choroidal thickness (white con
distance from the RPE to the chorioscleral interface in each of the manually segmented B-s
0.5 mm intervals up to 1.5 mm.Bland and Altman (1999). The intraclass correlation coefﬁcient
(ICC) was also calculated for each of the ocular parameters. The ICC
is an index of measurement reliability that ranges from 0 to 1, with
values of the ICC >0.75 having been suggested to represent excel-
lent measurement reliability; ICC 0.4 represents good reliability
and ICC< 0.4 to be poor (Portney and Watkins, 2008).
3. Results
3.1. Within-session repeatability
The within-session SD and coefﬁcient of variation generally
indicated highly precise measures for each of the ocular measure-
ments. The within-session SD ranged from 0.005 to 0.02 mm for
ocular biometrics (AL, CCT, ACD and LT), 0.002e0.012 mm for
subfoveal and parafoveal ChT, 0.003 mm for RT, 0.169 D for corneal
curvature, and 1.15 mm Hg for IOPcc. ICC analysis suggested
“excellent” reliability for all variables (ICC > 0.90 for all variables).
Table 1 illustrates the average within-session variability for each of
the ocular variables across all measurement sessions.
3.2. Subfoveal choroidal thickness
Repeated measures ANOVA demonstrated a signiﬁcant effect of
drug, and drug by time interaction for the change in subfovealverage of 30 individual B-Scans), and the analysis procedure performed on the images
r each subject. Manual segmentation deﬁned the inner limiting membrane, the outer
. Retinal thickness was deﬁned as the distance from the inner limiting membrane and
tinuous and dotted lines in the average B-scan respectively) were determined as the
cans. White bars represent the choroidal thickness measurements at the fovea and at
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sents the subfoveal choroidal thickness results for all subjects. The
instillation of 2% homatropine resulted in a small but signiﬁcant
increase in subfoveal ChT (mean change of 7 ± 3 mm, p < 0.0001 and
14 ± 2 mm, p < 0.0001) after 30 and 60 min respectively (Fig. 3).
Administration of 2.5% phenylephrine produced a small decrease in
ChT with a mean change of 1 ± 2 mm after 30 min that was not
statistically signiﬁcant (p ¼ 0.6) and a mean change of 2 ± 2 mm
after 60min that bordered on statistical signiﬁcance (p¼ 0.053). No
signiﬁcant changes in the subfoveal ChT from the baseline were
found with the placebo at any examination points (mean change
0 ± 1 mm and 0 ± 0 mm for 30 and 60 min respectively; p > 0.05).
There was also no signiﬁcant difference between the baseline
subfoveal ChT measurements (prior to drug instillation) for any of
the three conditions tested on different days (mean baseline ChT
were 343 ± 8 mm, 343 ± 8 mmand 344 ± 8 mm for the sessions for 2%
homatropine, 2.5% phenylephrine and placebo respectively).
3.3. Parafoveal choroidal thickness
Table 3 shows the mean changes in the parafoveal choroidal
thickness for the four (temporal, nasal, superior and inferior)
quadrants in 0.5 mm regions located 0.5, 1 and 1.5 mm from the
center of the fovea. Repeated measures ANOVA revealed the par-
afoveal choroid exhibited a similar increase in thickness as that
observed in the subfoveal choroid with time across all regions after
2% homatropine administration (drug by time interaction
p < 0.001). Fig. 4 shows the mean choroidal thickness changes
observed in the different parafoveal regions (averaged across all
quadrants) at 30 and 60 min post-instillation.Table 2
Effects of 2% homatropine, 2.5% phenylephrine and placebo on the mean change in
ocular parameters at 30 and 60 min from the baseline. Statistically signiﬁcant
ANOVA main effects and interactions (p < 0.05) are highlighted in bold. Asterisks
indicate signiﬁcant changes from baseline in the ocular parameter, from the Bon-
ferroni corrected pairwise comparisons (p < 0.05).Positive values represent an in-
crease in choroidal thickness, while the negative values correspond to a decrease in
choroidal thickness.
Mean change from baseline ANOVA
(Mean ± SD) p value
Drug
2%
homatropine
2.5%
phenylephrine
Placebo Drug Drug by
time
AL(mm) 0.723 0.001
30 min 4 ± 6 2 ± 4 2 ± 7
60 min 6 ± 6* 3 ± 5 3 ± 6
CCT (mm) 0.557 0.380
30 min 0 ± 2 0 ± 3 0 ± 2
60 min 1 ± 4 2 ± 5 0 ± 2
ACD (mm) 0.632 0.011
30 min 41 ± 25 14 ± 14 1 ± 9
60 min 57 ± 28* 23 ± 20 2 ± 9
LT (mm) 0.549 0.047
30 min 20 ± 23 2 ± 6 4 ± 10
60 min 25 ± 27* 4 ± 8 5 ± 9
RT (mm) 0.235 0.391
30 min 1 ± 3 1 ± 2 1 ± 4
60 min 1 ± 3 1 ± 3 0 ± 4
Subfoveal ChT (mm) <0.0001 <0.0001
30 min 7 ± 3* 1 ± 2 0 ± 1
60 min 14 ± 2* 1.5 ± 2 0 ± 0
Keratometry (D) 0.456 0.251
30 min 0.01 ± 0.21 0.02 ± 0.19 0.01 ± 0.15
60 min 0.05 ± 0.22 0.03 ± 0.21 0.03 ± 0.18
IOP (mm Hg) 0.485 0.168
30 min 0 ± 2 0 ± 2 1 ± 1
60 min 1 ± 1 1 ± 1 1 ± 2Overall, there was a very small decrease in choroidal thickness
30 and 60 min after administration of 2.5% phenylephrine in all
parafoveal regions; however the changes were not statistically
signiﬁcant (p > 0.05). Similarly, there was no statistically signiﬁcant
change in parafoveal choroidal thickness after placebo instillation
at the 30 and 60 min post-instillation measurements (p > 0.05 for
all comparisons).
3.4. Retinal thickness
Table 2 shows the mean change in foveal retinal thickness (RT)
from baseline for the three experimental conditions. On average,
retinal thickness at the fovea did not change in response to either
drug (average RT change was <1 mm, p > 0.05 for drug) and there
were no signiﬁcant drug by time interactions detected (p > 0.05).
3.5. Ocular biometry
Details of the mean ocular biometric changes following use of
the three different drugs are illustrated in Table 2. On average,
none of the anterior eye biometric measures (AL, CCT, corneal
curvature, ACD, and LT) exhibited signiﬁcant changes after instil-
lation of 2.5% phenylephrine or placebo at both 30 and 60 min
(p > 0.05 for all comparisons). In contrast, 60 min after adminis-
tration of 2% homatropine the axial length (AL) was signiﬁcantly
shorter (mean change, 6 ± 6 mm; p ¼ 0.001, drug by time
interaction). The anterior structures of the eye also demonstrated
signiﬁcant changes after homatropine instillation, with anterior
chamber depth (ACD) deepening (mean change 41 ± 25 mm; and
57 ± 28 mm for 30 and 60 min respectively) and the crystalline
lens (LT) thinning (mean change 20 ± 23 mm and 25 ± 28 mm).
Pairwise comparisons showed these changes were signiﬁcant for
ACD and LT at 60 min only (p < 0.05) (Table 2). IOP did not
signiﬁcantly change after the introduction of any of the three
pharmacological agents.
4. Discussion
The results of this study demonstrate that the anticholinergic
agent homatropine can increase choroidal thickness (7e14 mm) in
young healthy adults in both foveal and parafoveal regions, pre-
sumably by modifying choroidal autonomic nervous system activ-
ity. To our knowledge, this is the ﬁrst study to examine the
inﬂuence of homatropine upon choroidal thickness in human
subjects. Although the changes found were of small magnitude,
they highlight the importance of muscarinic mechanisms in the
regulation of choroidal thickness in human subjects.
The exact mechanism driving these changes is unclear; how-
ever, alterations in the tone of choroidal non-vascular smooth
muscle or changes in choroidal blood ﬂow have been suggested as
two likely causes of choroidal thickening after administration of
antimuscarinic drugs in animals (Nickla and Wallman, 2010). Evi-
dence of contraction of choroidal non-vascular smooth muscle in
response to increased parasympathetic stimulation (Meriney and
Pilar, 1987), and the recent ﬁnding of choroidal thickening
following double parasympathectomy in chicks (Nickla and
Schr€odl, 2012), suggests an involvement of parasympathetic
innervation and non-vascular smooth muscle in the choroidal
thickening response. These ﬁndings support a potential role of non-
vascular smooth muscle in the choroidal thickness changes that we
have observed with homatropine in humans, whose choroidal non-
vascular smooth muscle also has parasympathetic innervation
(Nickla and Wallman, 2010).
In contrast, it is generally accepted that acetylcholine (ACh)
released from parasympathetic cholinergic nerves is a powerful
Fig. 3. Mean change from baseline in subfoveal ChT at 30 and 60 min after drug instillation. Pairwise comparison revealed a signiﬁcant increase in choroidal thickness at 30 and
60 min after 2% homatropine administration (asterisk shows p < 0.0001) when compared to 2.5% phenylephrine and placebo (both p > 0.05). Error bars represent ± SD.
Table 3
Mean change in parafoveal choroidal thickness from the baseline after 30 and
60min of exposure to three different drugs for four choroidal quadrantswithin three
different regions. Asterisks indicate signiﬁcant changes from baseline in the ocular
parameter, from the Bonferroni corrected pairwise comparisons (p < 0.05). Positive
values represent an increase in choroidal thickness, while the negative values
correspond to a decrease in choroidal thickness.
Quadrant Region (mm) Time Change from baseline (mm) mean ± SD
Drug
2% Homatropine 2.5% Phenylephrine Placebo
Temporal 0.5 30 7 ± 4* 0 ± 1 0 ± 1
60 14 ± 4* 1 ± 2 0 ± 1
1.0 30 6 ± 3* 0 ± 2 0 ± 2
60 14 ± 3* 0 ± 2 0 ± 3
1.5 30 7 ± 2* 1 ± 1 0 ± 0
60 13 ± 3* 1 ± 3 1 ± 4
Nasal 0.5 30 7 ± 4* 1 ± 1 0 ± 2
60 11 ± 4* 1 ± 2 0 ± 1
1.0 30 7 ± 6* 0 ± 2 1 ± 2
60 13 ± *6 1 ± 2 1 ± 2
1.5 30 7 ± 3* 0 ± 2 0 ± 1
60 13 ± 5* 1 ± 3 1 ± 2
Superior 0.5 30 6 ± 3* 1 ± 1 0 ± 1
60 13 ± 4* 1 ± 1 0 ± 1
1.0 30 6 ± 3* 0 ± 2 1 ± 2
60 13 ± 2* 1 ± 1. 1 ± 2
1.5 30 4 ± 3* 0 ± 1 0 ± 1
60 10 ± 3* 1 ± 1 0 ± 2
Inferior 0.5 30 7 ± 4* 0 ± 1 0 ± 1
60 13 ± 4* 1 ± 1 0 ± 1
1.0 30 5 ± 4* 1 ± 2 1 ± 2
60 11 ± 3* 1 ± 2 0 ± 1
1.5 30 5 ± 5* 1 ± 1 1 ± 2
60 11 ± 5* 1 ± 1 1 ± 2
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release of endothelial nitric oxide (Toda and Nakanishi-Toda, 2007),
which would predict a vasoconstriction (and hence a possible
thinning of the choroid) in response to anticholinergic agents.
However, there is evidence from animal studies that anticholinergic
drugs such as atropine cause a vasodilation response in ocular
blood vessels, potentially through their action on pre-junctional
muscarinic receptors, thus increasing the release of neural nitric
oxide (Ayajiki et al., 2000). Therefore, it is possible that the mech-
anism involved in choroidal thickening observed in our study could
also involve the presynaptic inhibition of muscarinic receptors by
homatropine, resulting in increased neural NO release, and subse-
quent relaxation of smooth muscle.In animal studies, choroidal thickness and ocular growth
changes have been shown to be inﬂuenced by non-selective,
partially selective or highly selective muscarinic antagonists (i.e.,
atropine, pirenzepine, himbaicine, MT3, MT7) implicating musca-
rinic involvement in eye growth and myopia control (Arumugam
and McBrien, 2012; Luft et al., 2003; Diether et al., 2007). Results
from human clinical trials also indirectly support this hypothesis,
with outcomes demonstrating that daily administration of the non-
selective muscarinic antagonist 1% atropine, reduced the progres-
sion of myopia by about 60% during the second year of treatment,
and concentrations as low as 0.01% atropine still reduced eye
growth by 50% (Chua et al., 2006; Chia et al., 2012). In our study, the
change in ChT of the two myopic subjects in response to 2%
homatropine (14.1mm ± 3.1 at 60 min) was not substantially
different to the response of the remaining 12 emmetropic subjects
(13.7mm ± 3.5 at 60 min). Our study outcomes add to the evidence
that the muscarinic signalling blockage can also inﬂuence choroidal
thickness in the human eye, at least in the short term. Further
research is required to understand if there is a relationship between
these short term choroidal thickness changes in response to anti-
cholinergic agents and longer term changes in eye growth and
refractive error development.
The topical administration of 2.5% phenylephrine caused only a
small decrease in choroidal thickness that was not statistically
signiﬁcant. Increased activity of sympathetic adrenergic nerves
may be predicted to result in choroidal thinning predominantly due
to the contraction of vascular muscle cells that contain alpha-
adrenergic receptors. However, the exact role of non-vascular
smooth muscle cells in this process remains unknown. Previous
studies of the effect of phenylephrine on the human eye have
produced conﬂicting results, with some authors observing a
decrease in choroidal thickness in both the treated and fellow eyes
after topical phenylephrine administration (Kara et al., 2014),
whereas others have reported no change in choroidal thickness
(Bajenova et al., 2012). Similarly, reports on changes in choroidal
blood ﬂow as a result of stimulation of the sympathetic system are
also equivocal with both reductions in ocular blood ﬂow (Lanigan
et al., 1988; Takayama et al., 2009) and no change in posterior eye
circulation in healthy human subjects reported (Takayama et al.,
2004; Robinson et al., 1985; Schmetterer et al., 1996), In our
study, the lack of statistically signiﬁcant changes in choroidal
thickness may suggest that phenylephrine did not reach the pos-
terior pole at concentrations sufﬁcient to induce a direct vasomotor
effect. There are reports (Maurice and Mishima, 1984; Del Amo and
Urtti, 2008) suggesting that topical administration of the various
Fig. 4. Mean change from baseline in parafoveal ChT 30 and 60 min after drug instillation for average of 0 , 90 , 180 and 270 measurement meridians. Error bars represent ± SD.
The values under each of the bars on the x axis represent the distance in mm from the foveal center where each of the parafoveal choroidal thickness measurements were taken.
B.P. Sander et al. / Experimental Eye Research 128 (2014) 181e189 187mydriatic agents may not reach concentrations necessary to exert
an effect at the posterior pole. As the ﬁndings from human exper-
iments with phenylephrine have provided contradictory results,
further studies exploring the potential vasoconstrictive effects of
adrenergic stimulants on choroidal blood vessels and choroidal
thickness changes in human eyes may be warranted.
To our knowledge only one study (Mwanza et al., 2013) has
previously examined the effect of a muscarinic antagonist on par-
afoveal choroidal thickness and they reported no signiﬁcant dif-
ference in choroidal thickness after administration of 1%
tropicamide in healthy individuals and glaucoma patients. Contrary
to these ﬁndings by Mwanza et al. (2013), we did ﬁnd that topical
administration of homatropine produced increases in both sub-
foveal and parafoveal choroidal thickness. These differences in
choroidal responses to antimuscarinic agents may represent a dif-
ference in the posterior segment bioavailability of these two drugs
(Smith, 1976). The mechanism by which topically applied drugs can
reach the intraocular environment is through both a corneal and a
conjunctival/scleral penetration route. Penetration across the
cornea is proposed as the primary pathway by which drugs reach
the anterior segment after topical administration, whereas the
conjunctiva/scleral route is more important to allow access into
more posterior structures of the uveal tract (Hughes et al., 2005).
The relative contribution of this route is more important in case of
drugs that poorly penetrate across the cornea (Heier et al., 2009).
Since tropicamide shows a low afﬁnity and quick corneal pene-
tration (Smith, 1976), it is possible that the dose of the drug
reaching the posterior eye may be too low to induce choroidal
thickness changes.
Signiﬁcant changes in choroidal thickness after treatment with
2% homatropine were also accompanied by changes in axial length
observed 60 min after drug administration. The magnitude of these
changes was relatively small but statistically signiﬁcant, with an
average of 6 mm of decrease in axial length after the muscarinic
antagonist administration, with the direction of change (short-
ening) being consistent with previous studies in both avian species
(Nickla and Schr€odl, 2012) andmammals (Arumugam andMcBrien,
2012). Since the sub-foveal choroid increased in thickness by 14 mm
and the axial length decreased by 6 mm 60 min after homatropine
instillation, the unaccounted 8 mm may be the result of the
biomechanical forces on the globe associated with ciliary muscle
relaxation and changes in the iris that also led to signiﬁcant
deepening of the anterior chamber and lens thinning. Previous
animal (Nickla and Schr€odl, 2012; Lin et al., 1996; Schmid andWildsoet, 1996) and human (Drexler et al., 1997; Cheung et al.,
2009) studies have also reported a signiﬁcant variation in the
anterior chamber depth (ACD) and lens thickness (LT) measure-
ments after the administration of muscarinic antagonists or sur-
gical modiﬁcation of parasympathetic input to the eye, with trends
similar to the results obtained in our study. Pharmacologic
blockade of cholinergic transmission resulted in signiﬁcant
enlargement of ACD and thinning of the lens. In our data, the
magnitude of LT thinning was smaller than ACD deepening, sug-
gesting a possible posterior displacement of the lens.
Natural variations in choroidal thickness over the course of the
day, eye diseases or topical and systemic medications should be
considered as potential confounders in any studies reporting
choroidal thickness. Previous studies have found that the choroid
and axial length undergo signiﬁcant diurnal ﬂuctuations (Stone
et al., 2004; Brown et al., 2009; Chakraborty et al., 2011). The
choroid is typically thickest in the evening and thinnest around
noon, while AL changes are antiphase to the ChT variations. To
ensure consistency and minimize any inﬂuence from potential
diurnal variation, we tested all conditions at approximately the
same time of the day. Although our study included only health
young adult subjects, our ﬁndings highlight the potential impor-
tance of muscarinic mechanisms in the regulation of choroidal
thickness in humans. Future research, particularly in older subjects
with disease (who are more likely to be using medications) should
consider the potential for topical and/or systemic drugs that can
inﬂuence the muscarinic system, to be potential confounders in
studies of choroidal thickness.
5. Conclusions
Instillation of the anticholinergic agent 2% homatropine resulted
in an increase in subfoveal and parafoveal choroidal thickness in
young healthy adult subjects. Therefore the study results provide
important insight into the potential role of muscarinic mechanisms
in transient choroidal thickening in the human eye.
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